Pediatric Pertussis in Ambulatory Settings

Recruiting

• Conditions: Pertussis/Whooping Cough; Children, Only; Ambulatory

• Registration Number: NCT04807712
• Lead Sponsor: Association Clinique Thérapeutique Infantile du val de Marne

Brief Summary

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

Detailed Description

The whooping cough surveillance objectives are :

* to follow the duration of protection of the Ca vaccines in the context of modifications of the vaccine recommendations

* to describe the clinical characteristics of a population vaccinated with several boosters

* to adapt complementary examinations for diagnostic purposes (culture, PCR, serology) according to the evolution of scientific knowledge

* to monitor B. parapertussis infections

* to train laboratories with nasopharyngeal aspiration

* to monitor the evolution of the bacterial species All children aged 0-18 years, in whom the diagnosis of pertussis is mentioned and for which a biological check-up is requested, are included, except asymptomatic children with confirmed family case.

In case of suspected pertussis, real-time PCR and / or culture and / or (rarely) serology is / are still prescribed to the patient and / or his entourage.

Selected Pediatricians from the ACTIV group and the AFPA working in an outpatient clinic, located in different places in France, are participating in this network since 2001. The clinical evolution and the results of the examinations are transcribed on a case report form. The data are collected, firstly, during the visit where the diagnosis of whooping cough is suspected and a biological assessment requested (patient's medical history, clinical data, vaccination status and dates, as well as the search for a contaminated/contaminator) and secondly during the follow-up visit (results of the biological check-up and diagnosis, antibiotics potentially prescribed, and supplement data of the entourage, except in case of diagnosis of pertussis not retained).

All evaluations made by the pediatricians are regularly reviewed during meetings, and final diagnoses used are:

* biological pertussis

* epidemiological pertussis

* not evaluable

* lost of follow up

* no whooping cough

Study Timeline

• Study Start: 2001-05-30
• Study First Submitted: 2021-03-18
• Study First Submitted QC: 2021-03-18
• Study First Posted: 2021-03-19
• Status Verified: 2024-01
• Last Update Submitted: 2024-02-07
• Last Update Posted: 2024-02-08
• Primary Completion: 2030-01-01
• Study Completion: 2030-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 898

Inclusion Criteria

• All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested

Exclusion Criteria

• children without symptoms with a household confirmed case
• cases for which the pertussis diagnosis was not suspected by the pediatrician

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of pertussis vaccines protection	at inclusion	Evaluate the duration of protection of the Ca vaccines

Secondary Outcome Measures

Name	Time	Method
Clinical characteristics of pertussis	at inclusion	Describe the clinical characteristics of a population vaccinated

Trial Locations

Locations (1)

ACTIV; 🇫🇷 Créteil, France